Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20072439 | 0.85 | HDAC4 (0.46) | HDAC4HDAC8KDM4EALDH1A1ALOX12 | |
| SCHEMBL4547844 | 0.76 | IDO1 (0.36) | ALDH1A1ALOX12HTTSMN1; SMN2MAPT | |
| SCHEMBL8975041 | 0.75 | ACHE (0.44) | ALDH1A1TDP1SMN1; SMN2TP53LMNA | |
| SCHEMBL683932 | 0.74 | CYP3A4 (0.44) | HDAC4HDAC8KDM4EALDH1A1ALOX12 | |
| SCHEMBL14285751 | 0.73 | EGFR (0.39) | KDM4EALDH1A1CYP3A4MAPTHPGD | |
| SCHEMBL18720480 | 0.72 | HDAC4 (0.42) | HDAC4HDAC8KDM4EALDH1A1ALOX12 | |
| SCHEMBL13712745 | 0.71 | HPGD (0.41) | KDM4EALDH1A1ALOX12TDP1SMN1; SMN2 | |
| SCHEMBL13935537 | 0.70 | HDAC4 (0.38) | HDAC4HDAC8ALDH1A1HTTTDP1 | |
| SCHEMBL374780 | 0.70 | HDAC4 (0.56) | HDAC4HDAC8KDM4EALDH1A1ALOX12 | |
| SCHEMBL21102636 | 0.69 | CYP3A4 (0.40) | HDAC4HDAC8KDM4EALDH1A1ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546404-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME (US) | 2013-10-01 | — | — | US | disclosed |
| US-8148535-B2 | Potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-04-03 | — | — | US | disclosed |
| US-8067607-B2 | Potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-11-29 | — | — | US | disclosed |
| US-7807672-B2 | Compounds that are ERK inhibitors | SCHERING CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| US-20100004229-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2010-01-07 | — | — | US | disclosed |
| US-20090233897-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | disclosed |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
| US-7504411-B2 | 2,3,6-Trisubstituted-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-17 | — | — | US | disclosed |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPK10 | HDAC4 340/4885HDAC8 687/4885KDM4E 919/4885 |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPKAPK2 | HDAC4 499/4885HDAC8 791/4885KDM4E 1169/4885 |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPKAPK2 | HDAC4 499/4885HDAC8 791/4885KDM4E 1169/4885 |
| US-20100004229-A1 | Potassium Channel Inhibitors | KCNJ2, KCNH2, KCNH3 | HDAC4 1473/4885HDAC8 1652/4885KDM4E 418/4885 |
| US-20090233897-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | HDAC4 865/4885HDAC8 900/4885KDM4E 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.